What happened

Cronos Group (NASDAQ:CRON) stock jumped 13.6% in December, according to data from S&P Global Market Intelligence. That brought the Canadian marijuana grower stock's 2018 gain to 34.4%.

(As for 2019, Cronos stock started the year on a strong note, as it popped 13.1% during last week's holiday-shortened trading week.)

For context, last month shares of Cronos' main peers -- Canopy Growth, TilrayAurora Cannabis, and Aphria -- posted double-digit losses. 

Many $100 bills falling from the sky.

Image source: Getty Images.

So what

The catalyst for Cronos stock's rise last month was the company's announcement before the market open on Friday, Dec. 7, that tobacco giant Altria (NYSE:MO) is buying a 45% stake in Cronos for approximately $1.8 billion (about 2.4 billion Canadian dollars). The agreement also provides an opportunity for Altria to increase its ownership stake to up to 55% over the next four years.  

The deal didn't come as much of a surprise, as Cronos had announced earlier in that week that it was in preliminary talks with Altria about an investment, and rumors about such a deal had been swirling for some time.

Notably, this deal is the second-biggest ever in the legal cannabis industry, behind alcoholic beverage giant Constellation Brands$4.0 billion investment in Canopy Growth

Altria paid a 33% premium over Cronos stock's closing price on Nov. 30 and a 41.5% premium over the stock's 10-day volume-weighted average price through that same date. (Nov. 30 was "the last unaffected trading day prior to when Cronos Group announced it was in preliminary discussions with Altria regarding a possible investment," Cronos said in its press release about the deal.) 

Following the announcement, shares of Cronos gained 21.7% on Dec. 7. Through that date, they were up a whopping 39% in the month, before pulling back sharply, along with other marijuana stocks and, to a lesser degree, the market in general. 

Now what

Cronos' prospects improved significantly last month. An infusion of cash to the tune of $1.8 billion will go a long way in enabling the company to rapidly expand its business and otherwise compete in the fast-growing global legal cannabis market.

Moreover, the company's partnership with Altria should prove invaluable, as the tobacco leader has immense experience in selling products in highly regulated markets along with a vast distribution network. 

Beth McKenna has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.